Profile data is unavailable for this security.
About the company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
- Revenue in USD (TTM)82.55m
- Net income in USD-35.35m
- Incorporated2000
- Employees224.00
- LocationCellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
- Phone+33 181691600
- Fax+33 181691606
- Websitehttps://www.cellectis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Palisade Bio Inc | 0.00 | -11.23m | 269.70m | 8.00 | -- | 5.14 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
| Silence Therapeutics plc | 25.81m | -65.01m | 282.46m | 115.00 | -- | 3.35 | -- | 10.94 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Cellectis SA (ADR) | 82.55m | -35.35m | 289.56m | 224.00 | -- | 2.74 | -- | 3.51 | -0.3524 | -0.3524 | 0.8207 | 1.39 | 0.2234 | -- | 8.58 | 368,531.30 | -9.57 | -21.50 | -16.65 | -29.24 | -- | -32.79 | -42.82 | -220.86 | -- | -3.13 | 0.5013 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 289.64m | 275.00 | -- | 0.0316 | -- | 1.28 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 293.63m | 124.00 | -- | 1.73 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 298.59m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| TriSalus Life Sciences Inc | 40.21m | -72.25m | 299.66m | 110.00 | -- | -- | -- | 7.45 | -2.02 | -2.02 | 1.22 | -0.5357 | 1.26 | 1.76 | 8.11 | 365,518.20 | -123.81 | -- | -183.62 | -- | 84.04 | -- | -98.45 | -- | 2.75 | -6.61 | 5.43 | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| Rezolute Inc | 0.00 | -84.23m | 300.49m | 71.00 | -- | 2.34 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 308.24m | 28.00 | -- | 1.74 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 308.64m | 4.00 | -- | 1.38 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| C4 Therapeutics Inc | 35.95m | -104.99m | 309.32m | 104.00 | -- | 1.20 | -- | 8.60 | -1.36 | -1.36 | 0.4337 | 2.65 | 0.1015 | -- | 13.06 | 345,644.20 | -29.63 | -27.16 | -33.31 | -30.47 | -- | -- | -292.08 | -328.00 | -- | -- | 0.00 | -- | 1.02 | 1.61 | 0.3058 | -- | -1.36 | -- |
| CytoDyn Inc | 0.00 | -40.35m | 312.62m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -158.52m | 317.68m | 148.00 | -- | 2.28 | -- | -- | -2.51 | -2.51 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -80.43 | -40.80 | -97.39 | -43.86 | -- | -- | -- | -- | -- | -- | 0.1371 | -- | -- | -- | -71.21 | -- | 26.12 | -- |
| Neurogene Inc | 0.00 | -85.13m | 321.26m | 107.00 | -- | 1.15 | -- | -- | -4.12 | -4.12 | 0.00 | 17.97 | 0.00 | -- | -- | 0.00 | -37.67 | -27.58 | -40.40 | -29.44 | -- | -- | -- | -28,431.03 | -- | -- | 0.0001 | -- | -- | -- | -106.91 | -- | -1.67 | -- |
Data as of Mar 03 2026. Currency figures normalised to Cellectis SA's reporting currency: US Dollar USD
10.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The B Group, Inc.as of 31 Dec 2025 | 3.28m | 3.26% |
| Long Focus Capital Management LLCas of 31 Dec 2025 | 2.79m | 2.77% |
| UBS Asset Management (Americas) LLCas of 31 Dec 2025 | 1.87m | 1.86% |
| UBS Asset Management Switzerland AGas of 31 Dec 2025 | 1.30m | 1.30% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 345.87k | 0.34% |
| Nomura Investment Management Business Trustas of 31 Dec 2025 | 226.88k | 0.23% |
| Marshall Wace LLPas of 31 Dec 2025 | 178.47k | 0.18% |
| Citadel Securities LLCas of 31 Dec 2025 | 95.43k | 0.10% |
| Morgan Stanley & Co. International Plcas of 31 Dec 2025 | 84.84k | 0.08% |
| LPL Financial LLCas of 31 Dec 2025 | 84.79k | 0.08% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
